Cantor Fitzgerald Predicts Immatics FY2025 Earnings

Immatics (NASDAQ:IMTX) – Equities researchers at Cantor Fitzgerald issued their FY2025 earnings per share estimates for shares of Immatics in a report released on Tuesday, January 21st. Cantor Fitzgerald analyst E. Schmidt expects that the company will earn ($1.34) per share for the year. The consensus estimate for Immatics’ current full-year earnings is ($0.79) per share.

Several other research analysts also recently weighed in on the company. Piper Sandler began coverage on Immatics in a research note on Monday, October 7th. They set an “overweight” rating and a $19.00 target price for the company. The Goldman Sachs Group raised Immatics to a “strong-buy” rating in a research note on Monday, November 25th. Finally, Bank of America reduced their price objective on Immatics from $16.00 to $15.00 and set a “buy” rating for the company in a research note on Tuesday, November 19th. Four equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Buy” and a consensus target price of $16.67.

Immatics Price Performance

Shares of IMTX stock opened at $5.45 on Wednesday. The company has a market cap of $650.51 million, a price-to-earnings ratio of -8.26 and a beta of 0.77. The stock has a 50 day simple moving average of $7.22 and a 200-day simple moving average of $9.73. Immatics has a 1-year low of $5.27 and a 1-year high of $13.77.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in IMTX. Quarry LP increased its stake in shares of Immatics by 29.4% in the 3rd quarter. Quarry LP now owns 11,000 shares of the company’s stock worth $126,000 after acquiring an additional 2,500 shares during the last quarter. AlphaCentric Advisors LLC increased its stake in shares of Immatics by 25.0% in the 3rd quarter. AlphaCentric Advisors LLC now owns 25,000 shares of the company’s stock worth $285,000 after acquiring an additional 5,000 shares during the last quarter. Texas Capital Bank Wealth Management Services Inc acquired a new stake in shares of Immatics in the 3rd quarter worth $114,000. Forefront Analytics LLC acquired a new stake in shares of Immatics in the 2nd quarter worth $139,000. Finally, The Manufacturers Life Insurance Company increased its stake in shares of Immatics by 9.3% in the 3rd quarter. The Manufacturers Life Insurance Company now owns 164,766 shares of the company’s stock worth $1,880,000 after acquiring an additional 13,997 shares during the last quarter. 64.41% of the stock is owned by institutional investors and hedge funds.

About Immatics

Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the research and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as TCR-engineered autologous or allogeneic adoptive cell therapies (ACT) and antibody-like TCR Bispecifics.